Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Роль троспия хлорида (Спазмекс) в лечении мужчин с симптомами гиперактивного мочевого пузыря и аденомой предстательной железы
Роль троспия хлорида (Спазмекс) в лечении мужчин с симптомами гиперактивного мочевого пузыря и аденомой предстательной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Irwin DE, Milsom I, Hunskaar S et al. Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study. Eur Urol 2006; 50: 1306–15.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
3. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.
4. Michel MC, Chapple CR. Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol 2009; 27: 705–9.
5. Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377–86.
6. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416–9.
7. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931–7.
8. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–9.
9. Раснер П.И., Пушкарь Д.Ю. Медикаментозная терапия у больных аденомой предстательной железы и гиперактивным мочевым пузырем. Cons. Med. 2011; 13 (7): 12–5.
10. Witte LPW, Chapple CR, de la Rosette JJMCH, Michel MC. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 2008; 54: 326–34.
11. Jumadilova Z, Harris H, del Aguilla M et al. Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia. Presented at: The 35th Annual Meeting of the International Continence Society; August 28–September 2, 2005. Montreal, Canada.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011; 60 (1): 94–105.
13. Школьников М.Е. Спазмекс в лечении гиперактивного мочевого пузыря. Отечественный опыт применения. Урология. 2009; 6: 77–82.
14. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43 (2): 283–95.
15. Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002; 41: 6–14.
16. Wiedemann A, Kusche W, Neumeister C. Flexible Dosing of Trospium Chloride for the Treatment of OAB – Results of a Non-Interventional Study in 4,092 Patients. Open Clin Trials J 2011; 3: 1–5.
17. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.
18. Wiedemann A, Neumann G, Neumeister C et al. Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Non-Interventional Trial Showing Use of Flexible Dosing. UroToday Int J 2009; 2 (2).
19. Мазо Е.Б., Кривобородов Г.Г., Козырев С.В. и др. Троспиум хлорид в лечении идиопатической и нейрогенной детрузорной гиперактивности. Урология. 2005; 4: 56–9.
20. MacDiarmid SA, Ellsworth PI, Ginsberg DA et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011; 77 (1): 24–9.
2. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991; 338: 469–71.
3. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78.
4. Michel MC, Chapple CR. Basic mechanisms of urgency: roles and benefits of pharmacotherapy. World J Urol 2009; 27: 705–9.
5. Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011; 59: 377–86.
6. Hawthorn MH, Chapple CR, Cock M, Chess-Williams R. Urothelium-derived inhibitory factor(s) influence detrusor muscle contractility in vitro. Br J Pharmacol 2000; 129: 416–9.
7. Malone-Lee JG, Al-Buheissi S. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. BJU Int 2009; 103: 931–7.
8. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–9.
9. Раснер П.И., Пушкарь Д.Ю. Медикаментозная терапия у больных аденомой предстательной железы и гиперактивным мочевым пузырем. Cons. Med. 2011; 13 (7): 12–5.
10. Witte LPW, Chapple CR, de la Rosette JJMCH, Michel MC. Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 2008; 54: 326–34.
11. Jumadilova Z, Harris H, del Aguilla M et al. Agent selection for overactive bladder patients with and without documented comorbid benign prostatic hyperplasia. Presented at: The 35th Annual Meeting of the International Continence Society; August 28–September 2, 2005. Montreal, Canada.
12. Athanasopoulos A, Chapple C, Fowler C et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol 2011; 60 (1): 94–105.
13. Школьников М.Е. Спазмекс в лечении гиперактивного мочевого пузыря. Отечественный опыт применения. Урология. 2009; 6: 77–82.
14. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43 (2): 283–95.
15. Rovner ES, Wein AJ. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002; 41: 6–14.
16. Wiedemann A, Kusche W, Neumeister C. Flexible Dosing of Trospium Chloride for the Treatment of OAB – Results of a Non-Interventional Study in 4,092 Patients. Open Clin Trials J 2011; 3: 1–5.
17. Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.
18. Wiedemann A, Neumann G, Neumeister C et al. Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Non-Interventional Trial Showing Use of Flexible Dosing. UroToday Int J 2009; 2 (2).
19. Мазо Е.Б., Кривобородов Г.Г., Козырев С.В. и др. Троспиум хлорид в лечении идиопатической и нейрогенной детрузорной гиперактивности. Урология. 2005; 4: 56–9.
20. MacDiarmid SA, Ellsworth PI, Ginsberg DA et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology 2011; 77 (1): 24–9.
Авторы
М.Е.Школьников, Г.Г.Кривобородов, Н.С.Ефремов
Кафедра урологии ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ
Кафедра урологии ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.